Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
Shan Sakakibara filed to sell Class A shares of BLLN. The planned sale covers 4,000 Class A shares held at Fidelity Brokerage Services, with an aggregate market value of $560,840.00 as of an indicated reference price on NASDAQ. The filing also lists prior sales of Class A shares during the past three months, including three separate 8,000‑share transactions on June 8, 2026, June 24, 2026, and July 9, 2026, with aggregate values of $785,800.00, $880,000.00, and $1,000,000.00, respectively.
BillionToOne, Inc. executive Nancy JoAnn Johnson, Senior Vice President of Sales and Commercial Operations, reported selling an aggregate 14,199 shares of Class A Common Stock on July 16, 2026. The four open-market or private transactions, executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, were completed at weighted average prices between approximately $126.330 and $130.010 per share.
Nancy J. Johnson submitted a Form 144 in connection with potential sales of BLLN Class A shares through Fidelity Brokerage Services LLC, with trading on NASDAQ. She previously acquired Pre-IPO Class A shares from the issuer for cash on several dates between July 2020 and December 2021.
Within the past three months, Johnson sold 3,418 Class A shares on June 8, 2026 for $339,347.28, 10,582 shares on June 9, 2026 for $1,063,192.55, and 801 shares on July 1, 2026 for $100,055.90.
BillionToOne, Inc. executive ten Bosch John Roderick, SVP of Laboratory Operations, executed pre-arranged open-market sales of 4,251 shares of Class A Common Stock at $125.4600 per share on July 13, 2026, under a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. Chief Technology Officer and director David Tsao reported multiple open-market sales of Class A Common Stock on July 13, 2026, totaling 20,000 shares at weighted-average prices, with underlying trade ranges from $122.185 to $127.2981 per share as detailed in footnotes. He also exercised stock options for 20,000 shares at a $2.8000 exercise price from fully vested options, pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan exercised options to acquire 12,500 shares of Class A Common Stock at $2.80 per share and on the same date executed open-market sales of 12,500 shares in multiple transactions at weighted average prices between $125.00 and $128.295 per share. Following these trades, he held no shares of Class A Common Stock directly but continued to hold 575,000 stock options. The transactions were carried out under a Rule 10b5-1 trading plan, and the options are reported as fully vested and exercisable.
BillionToOne, Inc. Chief Product Officer Shan Riku Sakakibara reported open‑market sales of Class A Common Stock totaling 8,000 shares at $125.00 per share on July 9, 2026. On the same date, Sakakibara exercised stock options for 4,000 shares of Class A Common Stock at exercise prices of $30.78 and $8.65 per share. The company notes these trades were effected under a Rule 10b5‑1 trading plan and that the options exercised were fully vested and exercisable.
BLLN has a Form 144 notice for the planned sale of up to 20,000 Class A shares through Fidelity Brokerage Services LLC, tied to a stock option exercise, with a proposed aggregate value of $250,497.77 and an intended sale date of July 13, 2026 on NASDAQ. The filing also lists sales in the prior three months, including 20,000 Class A shares by David Tsao for $2,045,326.00 and 3,500 Class A shares by the Dt 2021 Irrevocable Trust for $355,145.00 on June 15, 2026.
BLLN reports a planned sale of Class A securities through Fidelity Brokerage Services LLC on NASDAQ. The filing lists 4,251 Class A securities associated with a proposed transaction dated July 13, 2026. It also discloses prior Class A transactions labeled as pre-IPO shares and cash sales.
Holder John R. Ten Bosch is reported as having sold Class A securities in the past three months, including 2,832 units for $287,363.04 on June 15, 2026 and 1,416 units for $169,920.00 on June 29, 2026.
BLLN shareholder Fidelity Brokerage Services LLC filed to sell 3,500 Class A shares on NASDAQ, with an aggregate market value of $439,110.00, targeting a sale date of July 13, 2026. The shares are Pre IPO Shares acquired from the issuer for cash on December 30, 2021. The filing also lists recent sales on June 15, 2026 of 20,000 Class A shares for $2,045,326.00 by David Tsao and 3,500 Class A shares for $355,145.00 by the Dt 2021 Irrevocable Trust.